August 2018 Focus: Pharma Innovators, Top 200 Medicines, First Year After Launch, AR/VR and more!

Jason D. Hanson was appointed president, CEO and director of enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs.

Thane Wettig was appointed to the newly created role of chief marketing officer and metabolic franchise head at Intarcia Therapeutics Inc.

Richard Klinghoffer, Ph.D., was named CEO of Presage Biosciences.

Genesis Drug Discovery & Development appointed Olesia Buiakova, M.D., Ph.D., as chief scientific officer.

As drug prices fall under increased scrutiny, payers and regulators are targeting some key initiatives that could change the dynamic of pharmacy benefit management over the next 12 months. These emerging trends point to potentially rougher terrain for drugmakers looking to increase market share as payers take a more active role in enforcing formularies.

Healthcare providers, payers, and pharma companies are not making significant strides toward consumer centricity despite increasing demands and competition for healthcare dollars, according to new research by the global brand and marketing consultancy Prophet.

Med Ad News spoke with the authors of Prophet’s study of customer centricity in health care to find out more about their research and recommendations.

Health care continues to be one of the top issues that voters want to hear candidates talk about during their 2018 congressional campaigns, according to the results of Kaiser Health’s June 2018 tracking poll.

Here are the top five factors affecting drug pricing and reimbursement and evidence landscape and the top five factors affecting accelerated drug approvals landscape in 2018, according to Decision Resources Group.